Previous close | 135.22 |
Open | 135.43 |
Bid | 133.05 x 900 |
Ask | 141.22 x 800 |
Day's range | 135.19 - 136.24 |
52-week range | 119.59 - 158.34 |
Volume | |
Avg. volume | 912,315 |
Market cap | 15.281B |
Beta (5Y monthly) | 0.90 |
PE ratio (TTM) | 20.25 |
EPS (TTM) | 6.71 |
Earnings date | 31 Jan 2024 - 05 Feb 2024 |
Forward dividend & yield | 2.84 (2.09%) |
Ex-dividend date | 16 Jan 2024 |
1y target est | 142.79 |
Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that it has been awarded a contract by the United States Centers for Disease Control and Prevention (CDC) designed to assess the burden of hepatitis C virus (HCV) in the United States